| Item Type | Name |
|
Concept
|
Renal Insufficiency, Chronic
|
|
Academic Article
|
The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group.
|
|
Academic Article
|
Diabetes and chronic kidney disease: tragedy and challenge.
|
|
Academic Article
|
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
|
|
Academic Article
|
The role of calcium antagonists in chronic kidney disease.
|
|
Academic Article
|
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
|
|
Academic Article
|
An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease.
|
|
Academic Article
|
Beta blockers in the management of chronic kidney disease.
|
|
Academic Article
|
Obesity and insulin resistance as risk factors for chronic kidney disease.
|
|
Academic Article
|
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease.
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
|
|
Academic Article
|
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
|
|
Academic Article
|
Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.
|
|
Academic Article
|
Low birth weight is associated with chronic kidney disease only in men.
|
|
Academic Article
|
Should beta-blockers be used to control hypertension in people with chronic kidney disease?
|
|
Academic Article
|
Cardiometabolic syndrome and chronic kidney disease: what is the link?
|
|
Academic Article
|
Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality.
|
|
Academic Article
|
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.
|
|
Academic Article
|
Glycemic control and cardiovascular disease in chronic kidney disease.
|
|
Academic Article
|
Overview of the KEEP international articles.
|
|
Academic Article
|
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
World Kidney Day: hypertension and chronic kidney disease.
|
|
Academic Article
|
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD.
|
|
Academic Article
|
Chronic kidney disease: a coronary heart disease equivalent?
|
|
Academic Article
|
Can ambulatory blood pressure serve as a biomarker for presence of chronic kidney disease?
|
|
Academic Article
|
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies.
|
|
Academic Article
|
KEEP launches follow-up initiative aimed at predicting the future.
|
|
Academic Article
|
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?
|
|
Academic Article
|
Hypertension guidelines and chronic kidney disease: physicians, please follow directions.
|
|
Academic Article
|
Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.
|
|
Academic Article
|
Diabetes, the kidney, and cardiovascular risk. Preface.
|
|
Academic Article
|
Assessment and management of vascular disease risk in patients with chronic kidney disease.
|
|
Academic Article
|
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.
|
|
Academic Article
|
Fixed-dose combination and chronic kidney disease progression: which is the best?
|
|
Academic Article
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
|
Academic Article
|
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
|
|
Academic Article
|
Hypertension awareness, treatment, and control in chronic kidney disease.
|
|
Academic Article
|
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease.
|
|
Academic Article
|
Kidney early evaluation program: a community-based screening approach to address disparities in chronic kidney disease.
|
|
Academic Article
|
Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Association of BP variability with mortality among African Americans with CKD.
|
|
Academic Article
|
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
|
|
Academic Article
|
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
|
|
Academic Article
|
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
|
|
Academic Article
|
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.
|
|
Academic Article
|
The author replies.
|
|
Academic Article
|
The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control.
|
|
Academic Article
|
Chronic kidney disease as a coronary artery disease risk equivalent.
|
|
Academic Article
|
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease.
|
|
Academic Article
|
Diabetic kidney disease: a report from an ADA Consensus Conference.
|
|
Academic Article
|
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
|
|
Academic Article
|
Chronic kidney disease: optimal blood pressure for kidney disease-lower is not better.
|
|
Academic Article
|
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
|
|
Academic Article
|
Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.
|
|
Academic Article
|
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
|
|
Academic Article
|
Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?
|
|
Academic Article
|
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
|
|
Academic Article
|
Both chronic kidney disease and nocturnal blood pressure associate with strokes in the elderly.
|
|
Academic Article
|
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
|
|
Academic Article
|
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program.
|
|
Academic Article
|
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
|
|
Academic Article
|
Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes.
|
|
Academic Article
|
New agents for hyperkalemia.
|
|
Academic Article
|
Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease.
|
|
Academic Article
|
Advances in treatment of hyperkalemia in chronic kidney disease.
|
|
Academic Article
|
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
|
|
Academic Article
|
The double challenge of resistant hypertension and chronic kidney disease.
|
|
Academic Article
|
Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
The Kidney in Hypertension.
|
|
Academic Article
|
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia.
|
|
Academic Article
|
Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease.
|
|
Academic Article
|
Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk.
|
|
Academic Article
|
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
|
|
Academic Article
|
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
|
|
Academic Article
|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
|
|
Academic Article
|
Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status.
|
|
Academic Article
|
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
|
|
Academic Article
|
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
|
|
Academic Article
|
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
|
|
Academic Article
|
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.
|
|
Academic Article
|
MY APPROACH to the elderly patient with resistant hypertension.
|
|
Academic Article
|
Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension.
|
|
Academic Article
|
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.
|
|
Academic Article
|
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.
|
|
Academic Article
|
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.
|
|
Academic Article
|
Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study.
|
|
Academic Article
|
How to Manage Hypertension in People With Diabetes.
|
|
Academic Article
|
Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
|
|
Academic Article
|
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
|
|
Academic Article
|
Evolution of Patiromer Use: a Review.
|
|
Academic Article
|
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
|
|
Academic Article
|
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
|
|
Academic Article
|
U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy.
|
|
Academic Article
|
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
|
|
Academic Article
|
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.
|
|
Academic Article
|
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
|
|
Academic Article
|
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
|
|
Academic Article
|
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply.
|
|
Academic Article
|
Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study.
|
|
Academic Article
|
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Intersection Between Chronic Kidney Disease and Cardiovascular Disease.
|
|
Academic Article
|
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
|
|
Academic Article
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes".
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
|
|
Academic Article
|
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension.
|
|
Academic Article
|
Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.
|
|
Academic Article
|
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
|
|
Academic Article
|
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
|
|
Academic Article
|
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.
|
|
Academic Article
|
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022.
|
|
Academic Article
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
|
Academic Article
|
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review.
|
|
Academic Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
|
|
Academic Article
|
Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design.
|
|
Academic Article
|
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial.
|
|
Academic Article
|
Successful treatment of refractory hypertension with bilateral nephrectomy in a patient with chronic kidney disease stage 3.
|
|
Academic Article
|
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
|
|
Academic Article
|
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
|
|
Academic Article
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
|
Academic Article
|
Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
|
|
Academic Article
|
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.
|
|
Academic Article
|
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
|
|
Academic Article
|
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
|
|
Academic Article
|
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
|
|
Academic Article
|
Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
|
|
Academic Article
|
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
|
|
Academic Article
|
Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
|
|
Academic Article
|
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
|
|
Academic Article
|
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
|
|
Academic Article
|
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes.
|
|
Academic Article
|
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
|
|
Academic Article
|
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
|
|
Academic Article
|
Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
|
|
Academic Article
|
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
|
|
Academic Article
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
|
|
Academic Article
|
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
|
|
Academic Article
|
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
|
|
Academic Article
|
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
|
|
Academic Article
|
Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
|
|
Academic Article
|
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
|
|
Academic Article
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
|
Academic Article
|
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study.
|
|
Academic Article
|
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
|
|
Academic Article
|
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials.
|
|
Academic Article
|
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|
|
Academic Article
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|
|
Academic Article
|
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Re-Dosing Triggers.
|
|
Academic Article
|
Real-world Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-control Hypertension and Stages 3 and 4 Chronic Kidney Disease.
|
|
Academic Article
|
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials.
|